- Home
- SJW vs JANX Comparison
SJW vs JANX Comparison
Compare SJW & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJW
- JANX
- Stock Information
- Founded
- SJW 1866
- JANX 2017
- Country
- SJW United States
- JANX United States
- Employees
- SJW N/A
- JANX N/A
- Industry
- SJW Water Supply
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- SJW Utilities
- JANX Health Care
- Exchange
- SJW Nasdaq
- JANX Nasdaq
- Market Cap
- SJW 1.9B
- JANX 1.6B
- IPO Year
- SJW N/A
- JANX 2021
- Fundamental
- Price
- SJW $54.86
- JANX $26.02
- Analyst Decision
- SJW Strong Buy
- JANX Strong Buy
- Analyst Count
- SJW 3
- JANX 7
- Target Price
- SJW $58.00
- JANX $94.29
- AVG Volume (30 Days)
- SJW 292.6K
- JANX 974.6K
- Earning Date
- SJW 04-28-2025
- JANX 05-20-2025
- Dividend Yield
- SJW 3.06%
- JANX N/A
- EPS Growth
- SJW 12.16
- JANX N/A
- EPS
- SJW 2.98
- JANX N/A
- Revenue
- SJW $766,656,000.00
- JANX $10,588,000.00
- Revenue This Year
- SJW $4.56
- JANX N/A
- Revenue Next Year
- SJW $4.70
- JANX $250.58
- P/E Ratio
- SJW $18.40
- JANX N/A
- Revenue Growth
- SJW 12.34
- JANX 30.99
- 52 Week Low
- SJW $44.91
- JANX $22.52
- 52 Week High
- SJW $62.18
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- SJW 44.97
- JANX 41.70
- Support Level
- SJW $53.20
- JANX $24.13
- Resistance Level
- SJW $55.94
- JANX $33.97
- Average True Range (ATR)
- SJW 1.55
- JANX 1.93
- MACD
- SJW -0.17
- JANX -0.51
- Stochastic Oscillator
- SJW 12.70
- JANX 29.57
About SJW SJW Group (DE)
SJW Group is a U.S. water utility services holding company that provides, stores, purifies and distributes water. The company predominantly operates in various Californian municipalities and also has operations in other states. Its operating segments include Water Utility Services and Real Estate Services. The majority of the company's revenue is derived from its water utility services segment.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.